PBAC's latest decision on Ripretinib: Recommended with restriction (2021). Considered for Advanced gastrointestinal stromal tumour (GIST) after failure of or intolerance to imatinib and sunitinib.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$115k/QALY
Range: $95k/QALY–$115k/QALY
Submissions
2
first 2021
Submissions
2
2021 → 2021
Eligible population
Patients with advanced unresectable or metastatic GIST who have progressed or are intolerant to imatinib and sunitinib.
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
PFS
Pivotal trial size
129 patients
Key trials
INVICTUS
Comparator
Best Supportive Care
Economic model
CUA
ICER note
ICER is stated in redacted form; the ranges are provided in footnotes to Table 4 and Table 1.
Submission history
Mar 2021: Recommended with restriction · Authority Required